Last 5 Days Trading Activity
|Date||Open Price||Close Price||High||Low||Volume|
Last 5 Days Short Activity
|Date||Short Volume||Total Volume||Short Percentage||Short Indicator|
* Short Mode
About Lescarden, Inc. (OTC: LCAR)
Since its inception in , Lescarden has devoted its resources to fund research and development of proprietary biologic materials with a focus on wound healing, clinical skin care, osteoarthritis and cancer applications. In the ensuing years, significant studies substantiated the ability of Catrix, Lescarden s proprietary cartilage powder, to function as a biological response modifier by stimulating the body s immune system. This response has significant, demonstrated benefits for chronic wound management, and has been investigated as a potential treatment for certain types of cancer. Further studies indicated that Catrix has potent anti inflammatory properties that could also be effective against diseases such as arthritis, scleroderma and psoriasis. lt br / gt lt br / gt With a solid clinical platform, the Company in recent years has focused its strategy toward pursuing marketing and licensing opportunities for fully developed products that have received patents and are ready for commercialization.
- William E. Luther / President
Current Share Structure
- Market Cap: $865,263 - 03/19/2018
- Issue and Outstanding: 63,622,316 - 08/26/2014
Daily Technical Chart for (OTC: LCAR)
Stay tuned for daily updates and more on (OTC: LCAR)
More to come on (OTC: LCAR)
Do your DD and if you choose, be ready to go!
The Research: All source information contained in this email is from the public sources mentioned below.
Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in LCAR is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of LCAR and does not buy, sell, or trade any shares of LCAR. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/